Compare · BSX vs MHUA
BSX vs MHUA
Side-by-side comparison of Boston Scientific Corporation (BSX) and Meihua International Medical Technologies Co. Ltd. (MHUA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and MHUA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX carries a market cap of $72.26B.
- Over the past year, BSX is down 53.1% and MHUA is down 81.0% - BSX leads by 27.9 points.
- BSX has hit the wire 10 times in the past 4 weeks while MHUA has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 0 for MHUA).
- Company
- Boston Scientific Corporation
- Meihua International Medical Technologies Co. Ltd.
- Price
- $49.86+1.73%
- $7.61-45.80%
- Market cap
- $72.26B
- -
- 1M return
- +9.58%
- -65.53%
- 1Y return
- -53.13%
- -81.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co., Ltd. engages in the manufacture and marketing of medical consumables in the People's Republic of China. It offers class I, II, and III disposable medical devices. The company's products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles. It also distributes disposable medical devices sourced from other manufacturers to customers in China. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.
Latest BSX
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
- SEC Form 10-Q filed by Boston Scientific Corporation
Latest MHUA
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- Meihua International Medical Technologies Co., Ltd. Received Nasdaq Delisting Notice
- Meihua International Announces 1-For-100 Reverse Share Split
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.
- SEC Form 424B3 filed by Meihua International Medical Technologies Co. Ltd.